Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Inclusion Criteria: * Age \> 18 years; * Diagnosis of histologically confirmed stages IB2 (\> 4 cm) to IVA prickle-cell carcinoma or adenocarcinoma or uterine cervix adenosquamous carcinoma, according to FIGO system,7 (see Appendix A for guidance about staging); * Measurable disease according to RECIST 1.139 or at least disease evaluable through imaging methods and/or gynecological examination (magnetic resonance imaging (MRI) scans within six weeks prior to randomization will be accepted, computed tomography will accepted in case MRI is contraindicated); * Indication of definitive treatment with chemotherapy and radiation therapy, at the investigator's discretion; * Performance status \< 2, according to the Eastern Cooperative Oncology Group criteria 40 (ECOG; see Appendix C); * Adequate body functions, indicated by:Serum creatinine \< 1.2 mg/100 mL; Creatinine clearance \> 60 mL/min (estimate); Bilirubin up to 1.5-fold the upper limit of normal (ULN) and transaminases, alkaline phosphatase and gamma-glutamyltransferase up to 2.5-fold the ULN; Leucocytes \> 3,000/μL; Neutrophils \> 1,500/μL; Hemoglobin \> 10 g/dL; Platelets \> 80,000/μL; * Signed informed consent form. Exclusion Criteria: * Para-aortic lymph nodes involvement through radiological and/or surgical staging, at investigator's discretion; * Current severe comorbidity that, in the investigator's opinion, would put the patient at a significantly higher risk or will jeopardize protocol compliance; * Current bowel inflammatory disease; * Current major neurological or psychiatric disease, including clinically significant dementia and seizures, at the investigator's discretion; * Known hypersensitivity or allergic reactions to study treatment; * Current uncontrolled hypercalcemia (\> 11,5 mg/dL, that is, grade \> 1 according to Common Terminology Criteria for Adverse Events \[CTCAE\] v4.02, of US National Cancer Institute)41; * Know HIV positive status (enrollment of patients with hepatitis B or C is at the investigator's discretion); * Pregnancy or lactation; * Female patients, as well as their partners, who wish to become pregnant or are unwilling to use an appropriate contraceptive method throughout the study period.